Critical Review: AcelRx Pharmaceuticals (ACRX) and Its Competitors
AcelRx Pharmaceuticals (NASDAQ: ACRX) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare AcelRx Pharmaceuticals to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
Insider & Institutional Ownership
23.3% of AcelRx Pharmaceuticals shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 28.1% of AcelRx Pharmaceuticals shares are held by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares AcelRx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AcelRx Pharmaceuticals Competitors||-5,492.74%||-451.92%||-42.73%|
Earnings & Valuation
This table compares AcelRx Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|AcelRx Pharmaceuticals||$15.57 million||-$35.16 million||-1.74|
|AcelRx Pharmaceuticals Competitors||$263.26 million||$68.25 million||-6.44|
AcelRx Pharmaceuticals’ rivals have higher revenue and earnings than AcelRx Pharmaceuticals. AcelRx Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings for AcelRx Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AcelRx Pharmaceuticals Competitors||766||3054||11240||227||2.71|
AcelRx Pharmaceuticals presently has a consensus price target of $6.83, indicating a potential upside of 259.65%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.73%. Given AcelRx Pharmaceuticals’ higher probable upside, equities research analysts plainly believe AcelRx Pharmaceuticals is more favorable than its rivals.
Risk and Volatility
AcelRx Pharmaceuticals has a beta of 3.04, suggesting that its stock price is 204% more volatile than the S&P 500. Comparatively, AcelRx Pharmaceuticals’ rivals have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.
AcelRx Pharmaceuticals rivals beat AcelRx Pharmaceuticals on 8 of the 12 factors compared.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.